Updated IMPLANON NXT Procedures Statement

SHINE SA, September 2020

The contraceptive implant (Implanon NXT) is one of the most effective contraceptives available. Along with the hormonal and copper IUDs, it is classified as Long Acting Reversible Contraception (LARC) which are recommended as first-line options for all people choosing to use contraception.

SHINE SA wish to alert clinicians to important updated information about Implanon NXT procedures following an update of the product information in January 2020. These changes have been made to avoid the large blood vessels and nerves within and around the sulcus between biceps and triceps and reflect published research.

RACGP offers new suite of IUD resources

RACGP, 25th August 2020

The newly released suite consists of five intrauterine device (IUD) resources, including a checklist and patient confirmation form, patient pre- and post-insertion checklist, practitioner checklist and disclaimer. Current evidence-based options for pain relief during IUD procedures are provided as an appendix.

Dr Amy Moten, Chair of the RACGP Specific Interests Sexual Health Medicine network, led development of the resources, which she says are designed to provide guidance and support to all Australian practitioners.

SEXUAL HEALTH MATTERS: new clinical podcast from SHINE SA

SHINE SA, May 2020

Filled with quality clinical guidance and tips for best practice, SHINE SA’s new Sexual Health Matters – Clinical Podcast delves into the intimate regions of the body and broaches the uncomfortable conversations necessary to ensure client safety and sexual/reproductive well-being.

Through discussion, interview and explanation, experienced sexual health clinicians raise awareness of guidelines, resources, research and emerging trends to ensure that clinicians everywhere can provide excellent sexual and reproductive care to improve client outcomes.

If you have a topic you would like us to cover in future podcasts, email courses@shinesa.org.au to let us know!

U.S. FDA Approves Evofem Biosciences’ Phexxi™, the First Non-Hormonal Prescription Gel for the Prevention of Pregnancy

Evofem Biosciences via PRNewswire, May 22nd 2020 

Evofem Biosciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Phexxi™ (lactic acid, citric acid and potassium bitartrate) vaginal gel for the prevention of pregnancy in females of reproductive potential for use as an on-demand method of contraception.

Phexxi is the first non-hormonal, on-demand, vaginal pH regulator contraceptive designed to maintain vaginal pH within the normal range of 3.5 to 4.5 – an acidic environment that is inhospitable to sperm.

Situational Report: Sexual and Reproductive Health Rights in Australia

Marie Stopes Australia, Updated 17 April 2020

Situational Report: Sexual and Reproductive Health Rights in Australia – A request for collaboration and action to maintain contraceptive and abortion care throughout the SARS-COV-2 / COVID-19 pandemic

Executive Summary

We are in a context of increased risk of unplanned pregnancy, reproductive coercion, sexually transmitted infections, lack of pregnancy options and a multitude of barriers to healthcare. Access to contraception and abortion throughout the pandemic will mitigate broader public health risks for years to come. 
.
At Marie Stopes Australia, during the pandemic we have had to:

 Cancel surgical abortion care lists- meaning women and pregnant people have had to continue with their pregnancies or are likely to seek a termination at a later gestation
 Reduce our national gestational limit for surgical abortion to 22 weeks
 Face increased costs in the provision of regional healthcare, having no other option than to charter private flights for clinical staff
 Continuously scramble for Personal Protective Equipment (PPE)
 Reduce in-clinic list capacity to enable physical distancing
 Reduce contraceptive services in order to prioritise abortion access
 Reduce financial support for clients experiencing financial hardship
 Face increased risk of staff fatigue and burn out
 Evolve models of care in an effort to maintain access to care. To address this situation, we need to review legislation and policy, evolve models of care, maintain people’s rights to access care and make healthcare more affordable.

Key recommendations at this point in the pandemic include:
 All Governments, health and hospital services, and health clinics must consider abortion an essential service with Category 1 classification
 Provide access to medical abortion via telehealth for people living in South Australia
 Increase medical abortion provision to 70 days/10 weeks gestation, supported by the  Pharmaceutical Benefits Scheme (PBS)
 All accredited sexual and reproductive healthcare providers should have access to the National Medical Stockpile for PPE
 Intrastate travel support is needed for clinical staff in order to maintain surgical abortion provision in regional and remote clinics
 Do not criminalise women and pregnant people who attempt unsafe abortion

[This report contains] further detail on these points and a longer list of recommendations that Australia will need to consider in o order to maintain sexual and reproductive health
rights throughout the pandemic.

 

 

NEW Fact Sheet for Health Professionals – Contraception During the COVID-19 Pandemic.

SHINE SA, 15/4/2020

SHINE SA have released a new Fact Sheet for health professionals: Contraception During the COVID-19 Pandemic.

Contraception is an essential service during the COVID-19 pandemic. This includes the provision of emergency contraception, access to long acting reversible contraception (LARC) and management of complications of LARC. Health professionals can continue to facilitate access to contraception via telehealth consults and limited face-to-face consultations where possible.

This Fact Sheet provides advice for health professionals on the provision and management of contraception during the COVID-19 pandemic. This includes LARC, combined hormonal contraception, emergency contraception, progestogen only pill and depot medroxyprogesterone acetate (DMPA).